# Tarlatamab for SCLC Brain Metastases

> **NCT07402343** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Maastricht University Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Brain Metastases, Adult

## Interventions

- **DRUG:** Tarlatamab

## Key facts

- **NCT ID:** NCT07402343
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-02
- **Final completion:** 2030-02
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07402343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07402343, "Tarlatamab for SCLC Brain Metastases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07402343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*